Because of the FDA's support of and activities around RFID, most pharmaceutical companies are now either actively involved in RFID pilots or they're anxiously watching and waiting for test results to be published and the next FDA report to be issued. They're also beginning to get a sense of the cost and effort it's going to take to become compliant.

The key thing for companies to understand is that the technology, in and of itself, is not the answer to meeting strategic business goals and objectives. It's the complex analysis of the tracking pedigree data, as well as the sensory data (which is collected via RFID tags), that will allow them to derive the greatest and most strategic operational benefits.